DTDawn Thompson

Dawn Thompson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dawn Thompson has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Investigation into ligand selectivity and bias at the formyl peptide receptor family

    by Christine E. Jack, Christina M. Thomson, Sergio Dall’ANgelo, Dawn Thompson, James N. Hislop


  • Open Access

    Bioactivity Profiles of Progressively Ring‐Fluorinated Cyclohexyl Motifs in the WKYMVm Peptide as Formylpeptide FPR2 Agonists and in Keto‐Piperazines as Antitrypanosome Agents

    by Mengfan He, Christina M. Thomson, Dawn Thompson, Vytautus Kuodis, Terry K. Smith, Sergio Dall’aNgelo, David O’hAgan

    A series of all‐ cis ‐ring‐fluorinated cyclohexylalanines with progressively increasing levels of vicinal fluorines, as well as 4‐fluorophenylalanine and pentafluoroarylphenylalanine is introduced into the WKYMVm peptide in place of its tyrosine residue, for assays against the G‐protein coupled formylpeptide receptor, FPR2. Selected all‐ cis ‐ring cyclohexylalanines of this class are also incorporated into a keto‐piperazine molecular scaffold to generate sp 3 ‐rich derivatives for assays against the parasite Trypanosoma brucei. For these cyclohexylalanine analogs bioactivity trends correlate progressively with the levels of fluorination in each of the case studies. Notably, the all‐ cis pentafluorocyclohexylalanine analog of the W‐peptide is least active perhaps correlating with the well‐known polarity of this ‘Janus face’ cyclohexane. Although the trend is also apparent in the anti‐trypanosomal assays of the keto‐piperazine derivatives, it is less so and some compounds are more active than the previously reported phenylalanine‐derived analog.


  • Open Access

    GRK5 regulates endocytosis of FPR2 independent of β-arrestins

    by Christine E. Jack, Emily M. Cope, Laura Lemel, Meritxell Canals, Julia Drube, Carsten Hoffmann, Asuka Inoue, James N. Hislop, Dawn Thompson


  • Open Access

    Fenretinide inhibits obesity and fatty liver disease but induces Smpd3 to increase serum ceramides and worsen atherosclerosis in LDLR−/− mice

    by Dawn Thompson, Shehroz Mahmood, Nicola Morrice, Sarah Kamli-Salino, Ruta Dekeryte, Philip A. Hoffmann, Mary K. Doherty, Philip D. Whitfield, Mirela Delibegović, Nimesh Mody

    Fenretinide is a synthetic retinoid that can prevent obesity and improve insulin sensitivity in mice by directly altering retinol/retinoic acid homeostasis and inhibiting excess ceramide biosynthesis. We determined the effects of Fenretinide on LDLR−/− mice fed high-fat/high-cholesterol diet ± Fenretinide, a model of atherosclerosis and non-alcoholic fatty liver disease (NAFLD). Fenretinide prevented obesity, improved insulin sensitivity and completely inhibited hepatic triglyceride accumulation, ballooning and steatosis. Moreover, Fenretinide decreased the expression of hepatic genes driving NAFLD, inflammation and fibrosis e.g. Hsd17b13, Cd68 and Col1a1. The mechanisms of Fenretinide’s beneficial effects in association with decreased adiposity were mediated by inhibition of ceramide synthesis, via hepatic DES1 protein, leading to increased dihydroceramide precursors. However, Fenretinide treatment in LDLR−/− mice enhanced circulating triglycerides and worsened aortic plaque formation. Interestingly, Fenretinide led to a fourfold increase in hepatic sphingomyelinase Smpd3 expression, via a retinoic acid-mediated mechanism and a further increase in circulating ceramide levels, linking induction of ceramide generation via sphingomyelin hydrolysis to a novel mechanism of increased atherosclerosis. Thus, despite beneficial metabolic effects, Fenretinide treatment may under certain circumstances enhance the development of atherosclerosis. However, targeting both DES1 and Smpd3 may be a novel, more potent therapeutic approach for the treatment of metabolic syndrome.


  • Open Access

    Fenretinide inhibits obesity and fatty liver disease but induces Smpd3 to increase serum ceramides and worsen atherosclerosis in LDLR-/- mice

    by Dawn Thompson, Shehroz Mahmood, Nicola Morrice, Sarah Kamli-Salino, Ruta Dekeryte, Philip Hoffmann, Mary K. Doherty, Philip D. Whitfield, Mirela Delibegović, Nimesh Mody

    Fenretinide is a synthetic retinoid that can prevent obesity and improve insulin sensitivity in mice by directly altering retinol/retinoic acid homeostasis and inhibiting excess ceramide biosynthesis. We determined the effects of Fenretinide on LDLR -/- mice fed high-fat/high-cholesterol diet +/- Fenretinide, a model of atherosclerosis and non-alcoholic fatty liver disease (NAFLD). Fenretinide prevented obesity, improved insulin sensitivity and completely inhibited hepatic triglyceride accumulation, ballooning and steatosis. Moreover, Fenretinide decreased the expression of hepatic genes driving NAFLD, inflammation and fibrosis e.g. Hsd17b13, Cd68 and Col1a1 . The mechanisms of Fenretinide’s beneficial effects in association with decreased adiposity were mediated by inhibition of ceramide synthesis, via hepatic DES1 protein, leading to increased dihydroceramide precursors. However, Fenretinide treatment in LDLR -/- mice enhanced circulating triglycerides and worsened aortic plaque formation. Interestingly, Fenretinide led to a 4-fold increase in hepatic sphingomyelinase Smpd3 expression, via a retinoic acid-mediated mechanism and a further increase in circulating ceramide levels, linking induction of ceramide generation via sphingomyelin hydrolysis to a novel mechanism of increased atherosclerosis. Thus, despite beneficial metabolic effects, Fenretinide treatment may under certain circumstances enhance the development of atherosclerosis. However, targeting both DES1 and Smpd3 may be a novel, more potent therapeutic approach for the treatment of metabolic syndrome.

  • Open Access

    Phosphoprotein enriched in astrocytes (PEA)-15 is a novel regulator of adipose tissue expansion

    by Pola J. Verschoor, Fiona H. Greig, Justin J. Rochford, Giovanni Levate, Mirela Delibegovic, Dawn Thompson, Alasdair Leeson-Payne, Ruta Dekeryte, Ruth Banks, Joe W. Ramos, et al.

    Excessive expansion of adipose tissue in obesity typically leads to overflow and accumulation of lipids in other tissues, causing fatty liver disease and atherosclerosis. The intracellular protein, phosphoprotein enriched in astrocytes (PEA)-15 has been linked to metabolic disease but its role in lipid storage has not been examined. To delineate the role of PEA-15 in adipose tissue, we placed PEA-15−/− mice on a high fat diet. These mice developed increased body weight and greater white adipose tissue expansion compared to high fat diet-fed wild type mice. This was due to increased adipocyte cell size in PEA-15−/− mice consistent with greater lipid storage capacity. Surprisingly, PEA-15−/− mice exhibited improvements in whole body insulin sensitivity, lower hepatic weight and decreased serum triglycerides indicating a protective phenotype. To determine effects on atherosclerosis, PEA-15−/− mice were crossed with the ApoE−/− mice on a high fat diet. Strikingly, these mice were protected from atherosclerosis and had less hepatic lipid accumulation despite increased adiposity. Therefore, we reveal for the first time that PEA-15 plays a novel role in regulating the expansion of adipose tissue. Decreasing PEA-15 expression increases the sequestering of lipids in adipose tissue, protecting other tissues in obesity, thereby improving metabolic health.


  • Open Access

    Response to comment by Moxon et al.

    by Dawn Thompson, Nicola Morrice, Louise Grant, Samantha Le Sommer, Emma K. Lees, Nimesh Mody, Heather M. Wilson, Mirela Delibegovic

    We would like to thank Clinical Science for the opportunity to respond to the letter [1] which suggests that while we have been able to show that PTP1B inhibitor, trodusquemine, decreases atherosclerotic plaque size as well as serum triglycerides and cholesterol, that we have not shown that it reverses the plaque size, using in vivo imaging techniques such as MRI scanning or ultrasound. Both Ldrl−/− and ApoE−/− mouse models are historically, very well characterized mouse models of atherosclerosis that rapidly develop atherosclerotic plaques under high-fat/high-cholesterol dietary conditions. However, we wanted to confirm this in our own hands, using the gold-standard technique of sectioning the aorta and staining with Oil Red O over time. We now present …

  • Open Access

    Pharmacological inhibition of protein tyrosine phosphatase 1B protects against atherosclerotic plaque formation in the LDLR−/− mouse model of atherosclerosis

    by Dawn Thompson, Nicola Morrice, Louise Grant, Samantha Le Sommer, Emma K. Lees, Nimesh Mody, Heather M. Wilson, Mirela Delibegovic

    Cardiovascular disease (CVD) is the most prevalent cause of mortality among patients with type 1 or type 2 diabetes, due to accelerated atherosclerosis. Recent evidence suggests a strong link between atherosclerosis and insulin resistance, due to impaired insulin receptor (IR) signalling. Here, we demonstrate that inhibiting the activity of protein tyrosine phosphatase 1B (PTP1B), the major negative regulator of the IR prevents and reverses atherosclerotic plaque formation in an LDLR−/− mouse model of atherosclerosis. Acute (single dose) or chronic PTP1B inhibitor (trodusquemine) treatment of LDLR−/− mice decreased weight gain and adiposity, improved glucose homeostasis and attenuated atherosclerotic plaque formation. This was accompanied by a reduction in both, circulating total cholesterol and triglycerides, a decrease in aortic monocyte chemoattractant protein-1 (MCP-1) expression levels and hyperphosphorylation of aortic Akt/PKB and AMPKα. Our findings are the first to demonstrate that PTP1B inhibitors could be used in prevention and reversal of atherosclerosis development and reduction in CVD risk.


  • Open Access

    Identification of a Novel Recycling Sequence in the C-tail of FPR2/ALX Receptor

    by Dawn Thompson, Simon McArthur, James N. Hislop, Roderick J. Flower, Mauro Perretti